| Q35148054 | (18)F-Fluorothymidine PET-CT for resected malignant gliomas before radiotherapy: tumor extent according to proliferative activity compared with MRI. |
| Q74410453 | A population-based study of glioblastoma multiforme |
| Q49129538 | Adenoviral vector-mediated gene transfer: timing of wild-type p53 gene expression in vivo and effect of tumor transduction on survival in a rat glioma brachytherapy model |
| Q70957519 | Advances in radiation therapy for brain tumors |
| Q37222866 | Advances in radiotherapy of brain tumors: radiobiology versus reality |
| Q48483837 | Angiogenic patterns and their quantitation in high grade astrocytic tumors |
| Q40984051 | Central pathology review in clinical trials for patients with malignant glioma. A Report of Radiation Therapy Oncology Group 83-02. |
| Q35196741 | Comparison of dose distributions hippocampus in high grade gliomas irradiation with linac-based imrt and volumetric arc therapy: a dosimetric study |
| Q48421519 | Continuous hyperfractionated accelerated radiotherapy in the treatment of high-grade astrocytomas |
| Q48616460 | Cost-utility analysis of a malignant glioma protocol |
| Q38045432 | Current challenges in clinical target volume definition: tumour margins and microscopic extensions |
| Q41611838 | Current perspectives in gliomas |
| Q40429582 | Establishment and characterization of a new human glioblastoma cell line, NYGM. |
| Q34635798 | Factors affecting risk of symptomatic temporal lobe necrosis: significance of fractional dose and treatment time |
| Q36691999 | High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours |
| Q34539545 | High-dose chemotherapy with autologous stem cell rescue for brain tumors |
| Q55470753 | High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison. |
| Q48491367 | High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme |
| Q46415677 | Human interferon beta, nimustine hydrochloride, and radiation therapy in the treatment of newly diagnosed malignant astrocytomas |
| Q55233326 | Hyperfractionated and Hypofractionated Radiation Therapy for Human Malignant Glioma Xenograft in Nude Mice |
| Q41524743 | Hyperfractionated and accelerated radiation therapy in central nervous system tumors (malignant gliomas, pediatric tumors, and brain metastases) |
| Q48276729 | Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme |
| Q44922339 | Hyperfractionated radiation therapy for incompletely resected supratentorial low-grade glioma: a 10-year update of a phase II study |
| Q41482096 | Hyperfractionation: where do we stand? |
| Q40531161 | Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme |
| Q36365570 | Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or hope for the future? |
| Q73370388 | Impact of the interfraction interval on clonogenic cell survival in split-dose irradiation of R1H rhabdomyosarcoma of the rat in vitro |
| Q36081097 | Improving the acceptability of high-dose radiotherapy by reducing the duration of treatment: accelerated radiotherapy in high-grade glioma |
| Q34239497 | Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study |
| Q45015296 | Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach |
| Q43622605 | Influence of interfraction interval on the efficacy and toxicity of hyperfractionated radiotherapy in combination with concurrent daily chemotherapy in stage III non-small-cell lung cancer |
| Q44274009 | Interfraction interval does not affect survival of patients with non-small cell lung cancer treated with chemotherapy and/or hyperfractionated radiotherapy: a multivariate analysis of 1076 RTOG patients |
| Q37098119 | Interfractional variation of radiation target and adaptive radiotherapy for totally resected glioblastoma |
| Q39220867 | Management of GBM: a problem of local recurrence. |
| Q37476857 | Management of newly diagnosed glioblastoma: guidelines development, value and application |
| Q55479921 | Microvessel density is a prognostic indicator for patients with astroglial brain tumors. |
| Q48276896 | Modifying radical radiotherapy in high grade gliomas; shortening the treatment time through acceleration |
| Q55472680 | Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. |
| Q48100633 | NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients |
| Q37159513 | Optimizing radiotherapy schedules for elderly glioblastoma multiforme patients |
| Q30660196 | Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or < or = 20 cm(2), respectively) in the treatment of newly-diagnosed radiosurgery-ineli |
| Q31861401 | Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme |
| Q33329329 | Pre-irradiation carboplatin and etoposide and accelerated hyperfractionated radiation therapy in patients with high-grade astrocytomas: a phase II study |
| Q33315042 | Prospective single-arm study of 72 Gy hyperfractionated radiation therapy and combination chemotherapy for anaplastic astrocytomas |
| Q48651179 | Quality-adjusted survival analysis of malignant glioma patients |
| Q26827957 | Radiation and concomitant chemotherapy for patients with glioblastoma multiforme |
| Q48961365 | Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults |
| Q48716370 | Radiosurgery and accelerated radiotherapy for patients with glioblastoma |
| Q33779136 | Radiotherapy and temozolomide for newly diagnosed glioblastoma and anaplastic astrocytoma: validation of Radiation Therapy Oncology Group-Recursive Partitioning Analysis in the IMRT and temozolomide era. |
| Q33184436 | Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review |
| Q36882380 | Radiotherapy of glioblastoma |
| Q37108692 | Recurrence patterns in patients with high-grade glioma following temozolomide-based chemoradiotherapy |
| Q43742085 | Safety of thrice-daily hyperfractionated radiation and BCNU for high-grade gliomas |
| Q48734318 | Short course radiotherapy is an appropriate option for most malignant glioma patients |
| Q55476409 | Short-course radiotherapy in elderly and frail patients with glioblastoma multiforme. A phase II study. |
| Q41005740 | Speech and language disorders in patients with high grade glioma and its influence on prognosis |
| Q72054609 | Stereotactic radiosurgery as an adjunct to surgery and external beam radiotherapy in the treatment of patients with malignant gliomas |
| Q37144178 | Stereotactic radiosurgery for glioblastoma: retrospective analysis |
| Q30605562 | Target volumes in radiotherapy for high-grade malignant glioma of the brain. |
| Q40560864 | The basis for current treatment recommendations for malignant gliomas |
| Q55480630 | The relationship between the technical accuracy of stereotactic interstitial implantation for high grade gliomas and the pattern of tumor recurrence |
| Q36506770 | Treatments for astrocytic tumors in children: current and emerging strategies |
| Q30638278 | Vascular microenvironment in gliomas |
| Q55477998 | [3-Dimensional irradiation planning in brain tumors. The advantages of the method and the clinical results]. |